Viktoriya Grikh

Dr. Viktoriya Grikh


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EBElena Bakhrushina
Elena Bakhrushina
MSMarina M. Shumkova
Marina M. Shumkova
YAYana V. Avdonina
Yana V. Avdonina
AAArsen A. Ananian
Arsen A. Ananian
MBMina Babazadeh
Mina Babazadeh
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Transdermal drug delivery (TDD) is an increasingly important non-invasive method for administering active pharmaceutical ingredients (APIs) through the skin barrier, offering advantages such as improved therapeutic efficacy and reduced systemic side effects. As demand increases for patient-friendly and minimally invasive treatment options, TDD has attracted substantial attention in research and clinical practice. This review summarizes recent advances enhancing skin permeability through chemical enhancers (e.g., ethanol, fatty acids, terpenes), physical (e.g., iontophoresis, microneedles, sonophoresis), and nanotechnological methods (e.g., liposomes, ethosomes, solid lipid nanoparticles, and transferosomes). A comprehensive literature analysis, including scientific publications, regulatory guidelines, and patents, was conducted to identify innovative methods and materials used to overcome the barrier properties of the stratum corneum. Special emphasis was placed on in vitro, ex vivo, and in vivo evaluation techniques for such as Franz diffusion cells for assessing drug permeation and skin interactions. The findings highlight the importance of active physical methods, passive nanostructured systems, and chemical penetration enhancers. In conclusion, integrating multiple analytical techniques is essential for the rational design and optimization of effective transdermal drug delivery systems.

6 June 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EBElena Bakhrushina
Elena Bakhrushina
Svetlana Andreevna TitovaSvetlana Andreevna Titova
Svetlana Andreevna Titova
PSPolina S. Sakharova
Polina S. Sakharova
OPOlga N. Plakhotnaya
Olga N. Plakhotnaya
VGViktoriya Grikh
Viktoriya Grikh
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Stimuli-sensitive (in situ) drug delivery systems are a dynamically developing area of pharmaceutical research. Over the past decade, the number of studies on such systems has doubled. Among these, phase-inversion (or phase-sensitive) formulations, which were among the earliest proposed, offer significant advantages, including enhanced stability and stimuli-responsiveness. However, phase-inversion systems have remained relatively understudied. Despite the existence of three patented technologies (Atrigel®, BEPO®, FluidCrystal®) for delivery systems utilizing phase inversion for various routes of administration, the absence of unified approaches to development and standardization has significantly impeded the introduction of novel, effective drugs into clinical practice. This review examined the main polymers and solvents used to create phase-inversion compositions and discussed the feasibility of introducing other excipients to modify the systems’ physicochemical properties. The most commonly used polymers included polylactide-co-glycolide, shellac, and polylactic acid. The most frequently used solvents were N-methylpyrrolidone and dimethyl sulfoxide. Following an analysis of clinical studies of phase-sensitive drugs conducted over the past 25 years, as well as original research indexed in PubMed, ScienceDirect, and Google Scholar, the main problems hindering the broader adoption of phase-inversion systems in clinical practice were identified, and recommendations for further development in this promising area were provided.

28 August 2023 in Gels
Verified
Journal Article
Open access
PDF file
EBElena Bakhrushina
Elena Bakhrushina
ADAnastasia I. Dubova
Anastasia I. Dubova
MNMaria Nikonenko
Maria Nikonenko
VGViktoriya Grikh
Viktoriya Grikh
MSMarina M. Shumkova
Marina M. Shumkova
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
The main method of treatment and prevention of endophthalmitis is a combination of intravitreal and topical administration of antibiotics, such as cefuroxime moxifloxacin or vancomycin. However, this method is ineffective due to the rapid elimination of the drug. This problem can be solved with the help of intravitreal in situ injection systems, which are injected with a syringe into the vitreous body and provide prolonged action of the drug at the focus of inflammation. Under the influence of temperature, the liquid drug undergoes a phase transition and turns into a gel after injection. This ensures its prolonged action. The study aimed to develop an intravitreal in situ cefuroxime delivery system for the treatment of endophthalmitis based on a thermosensitive biodegradable composition of poloxamer 407 and hyaluronic acid. A combination of poloxamer Kolliphor® P407, Kolliphor® P188, and PrincipHYAL® hyaluronic acids of different molecular weights was used as a delivery system. The potency of cefuroxime solid dispersion with polyvinylpyrrolidone-10000, polyethylene glycol-400, and polyethylene glycol-1500 in a 1:2 ratio was studied for prolonged action compared to cefuroxime substance. The experimental formulations were studied for the parameters of gelation temperature in a long-term test (4 months), pH, and release of cefuroxime using dialysis bags. To study the distribution parameter in the vitreous body, an in vitro model (1/13) was developed, which was a hollow agar sphere filled with 1% (w/v) polyacrylate gel. For the superior formulations, a HET-CAM test (chorioallantoic membrane test) was performed to determine the absence of irritant effects. According to the study results, a formulation containing a solid dispersion of cefuroxime:PEG-400 (1:2), the matrix of which contained 18% (w/v) Kolliphor® P407 poloxamer, 3% (w/v) Kolliphor® P188 poloxamer, and 0.5% (w/v) hyaluronic acid (1400–1800), was selected. This sample had an average gelation temperature of 34.6 °C, pH 6.7 ± 0.5, and a pronounced prolonged effect. Only 7.6% was released in 3 h of the experiment, whereas about 38% of cefuroxime was released in 72 h. No irritant effect on the chorioallantoic membrane was observed for any formulations studied.

Verified
Journal Article
Open access
PDF file
IIIgor R Ilyasov
Igor R Ilyasov
ABArcady Braun
Arcady Braun
VOVera Olicheva
Vera Olicheva
VGValery Goman
Valery Goman
VGViktoriya Grikh
Viktoriya Grikh
VBVladimir Beloborodov
Vladimir Beloborodov
Herein, an automated, parameter-based workflow is introduced for processing time-resolved high-resolution mass spectrometry (HRMS) data. Its utility is demonstrated using the reaction between the ABTS•+ radical cation and the polyphenolic antioxidant naringenin. Data were collected using HRMS coupled to high-performance liquid chromatography (HPLC) in negative ion mode. The algorithm compares sequential time-resolved HRMS measurements to generate kinetic curves and calculate parameters for every detected species. Based on these curves and parameters, we can tentatively classify each species as a reagent, intermediate, or product. The algorithm was implemented as Java-based software. As a result, extensive data arrays of 1.3 million m/z-intensity pairs per experimental series were processed automatically. The workflow generated manageable candidate sets in each replicate series. Cross-replicate matching using a 5 ppm mass tolerance retained 29 ion tracks consistently detected in all three reaction runs for subsequent analysis. These ions can then be examined manually to identify compound structures. Overall, the approach provides a screening tool for untargeted reaction monitoring and supports subsequent structural annotation in complex chemical systems.